Biological evaluation of chalcones derivatives as potential anticancer agents : (Record no. 175123)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05584namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20251103105031.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 251021s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| Language code of sung or spoken text | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 572 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 572 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.12.21.Ph.D.2025.No.B |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Norhan Yasser Sayed Moaz, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Biological evaluation of chalcones derivatives as potential anticancer agents : |
| Remainder of title | In vitro study / |
| Statement of responsibility, etc. | by Norhan Yasser Sayed Moaz ; Supervisor Prof.Dr. Ismail Abdelshafy Abdelhamid, Prof.Dr. Haidan Mostafa Salem, Dr. Shaymaa Mohamed Eissa, Dr. Farid Mohamed Ahmed Sroor. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | التقييم البيولوجي لمشتقات الشالكون كعوامل محتملة مضادة للسرطان : |
| Remainder of title | دراسة معملية / |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 85 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 73-83. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | A novel series of pyrazolyl-chalcone derivatives was synthesized using Claisen-Schmidt condensation. The desired chalcone derivatives 7a-d and 9a-f were collected in high-quality via reacting the appropriate heteroaryl aldehyde derivatives with 4-acetyl-5-thiophene-pyrazole. The novel chalcones have undergone full elemental analysis, 1H-NMR, 13C-NMR, mass spectrometry, in addition to IR characterization. The novel chalcone derivatives 7a-d and 9a-f were studied in vitro as anti-cancer therapeutic against three human cancer cell lines; MCF7 (human Caucasian breast adenocarcinoma), PACA2 (pancreatic carcinoma), and PC3 (prostatic cancer) along with normal cell line BJ1 (normal skin fibroblasts). Compound 9e appeared to be the most promising compound, with IC50 = 27.6 µM against PACA2 cells in comparison with the reference drug doxorubicin (IC50 = 52.1 µM), and compound 7d exhibited anticancer activity with IC50 = 42.6 µM against MCF7 cells compared to the reference drug doxorubicin (IC50 = 48 µM). The DNA damage values and the DNA fragmentation percentages besides the gene expression for compounds 9e and 7d were determined on the pancreatic and breast cell lines. Furthermore, the molecular docking evaluation of compounds 7d and 9e was deliberated. The binding energies of compound 9e toward P53 mutant Y220C was -22 kcal/mole, however that of compound 7d towards Bcl-2 and CDK4 were -27.81 and -26.9 kcal/mole, respectively, compared to the standard values (-15.82, -33.96 and -29.9 kcal/mole). |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | تم تصنيع سلسلة جديدة من مشتقات بيرازول الشالكون باستخدام تكثيف كلايزن-شيمت. تم جمع مشتقات الشالكون المطلوبة 7a-d و9 a-f بجودة عالية من خلال تفاعل مشتقات الألدهيد المتغايرة المناسبة مع 4-أسيتيل-5-ثيوفين-بيرازول. خضعت الشالكونات الجديدة لتحليل كامل للعناصر الرنين المغناطيسي النووي ح، الرنين المغناطيسي النووي 13-كاربون ، وقياس الطيف الكتلي، بالإضافة إلى توصيف الأشعة تحت الحمراء. تمت دراسة مشتقات الشالكون الجديدة 7a-d و 9a-f في المختبر كعلاج مضاد للسرطان ضد ثلاثة خطوط خلايا سرطانية بشرية (سرطان الثدي، سرطان البنكرياس، سرطان البروستاتا) بالاضافه إلى خط الخلايا الطبيعي الخلايا الليفية الجلدية الطبيعية. يبدو أن المركب 9 هـ هو المركب الواعد، مع تركيز50% مثبط =6. 27 ضد خطوط خلايا سرطان البنكرياس مقارنه بالدوكسوروبيسين (2. 51) بينما مركب 7 د مع تركيز50% مثبط =6. 42 ضد خطوط خلايا سرطان الثدي مقارنه بالدوكسوروبيسين (48) . باستخدام خطوط خلايا الثدي والبنكرياس، التعبير الجيني، تلف الحمض النووي، وتم تقييم النسب المئوية لتجزئة الحمض النووي للمركبين 7 د و 9 هـ. علاوة على ذلك، الجزيئي تم تقييم دراسة الالتحام للمركبين 7 د و 9 هـ. التقارب الملزم للمركب 9 هـ نحو P53 Y220C المتحولة −22 سعرة حرارية لكل شامة، في حين أن المركب 7 د نحو Bcl2 و CDK4 −27.81 و −26.9 سعرة حرارية ، على التوالي، مقارنة بالقيم القياسية (−15.82 و −33.96 و−29.9 سعرة حرارية). |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biochemistry |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Chalcone |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ismail Abdelshafy Abdelhamid |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Haidan Mostafa Salem |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Shaymaa Mohamed Eissa |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Farid Mohamed Ahmed Sroor |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Ismail Abdelshafy Abdelhamid |
| -- | Haidan Mostafa Salem |
| -- | Shaymaa Mohamed Eissa |
| -- | Farid Mohamed Ahmed Sroor |
| Universities | Cairo University |
| Faculties | Faculty of Science |
| Department | Department of Zoology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 21.10.2025 | 92232 | Cai01.12.21.Ph.D.2025.No.B | 01010110092232000 | 21.10.2025 | 21.10.2025 | Thesis |